The relationship between sales of SSRI, TCA and suicide rates in the Nordic countries

Zahl, Per-Henrik; De Leo, Diego; Ekeberg, Øivind; Hjelmeland, Heidi; Dieserud, Gudrun
January 2010
BMC Psychiatry;2010, Vol. 10, p62
Academic Journal
Background: In the period 1990-2006, strong and almost equivalent increases in sales figures of selective serotonin re-uptake inhibitors (SSRIs) were observed in all Nordic countries. The sales figures of tricyclic antidepressants (TCAs) dropped in Norway and Sweden in the nineties. After 2000, sales figures of TCAs have been almost constant in all Nordic countries. The potentially toxic effect of TCAs in overdose was an important reason for replacing TCAs with SSRIs when treating depression. We studied whether the rapid increase in sales of SSRIs and the corresponding decline in TCAs in the period 1990-98 were associated with a decline in suicide rates. Methods: Aggregated suicide rates for the period 1975-2006 in four Nordic countries (Denmark, Finland, Norway and Sweden) were obtained from the national causes-of-death registries. The sales figures of antidepressants were provided from the wholesale registers in each of the Nordic countries. Data were analysed using Fisher's exact test and Pearson's correlation coefficient. Results: There was no statistical association (P = 1.0) between the increase of sales figures of SSRIs and the decline in suicide rates. There was no statistical association (P = 1.0) between the decrease in the sale figures of TCAs and change in suicide rates either. Conclusions: We found no evidence for the rapid increase in use of SSRIs and the corresponding decline in sales of TCAs being associated with a decline in the suicide rates in the Nordic countries in the period 1990-98. We did not find any inverse relationship between the increase in sales of SSRIs and declining suicide rates in four Nordic countries.


Related Articles

  • Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy. de Beaurepaire, Renaud; Honig, Adriaan; MacQueen, Glenda // Current Medical Literature: Psychiatry;2011, Vol. 22 Issue 2, p73 

    The article discusses a study on the efficacy, tolerability and safety of antidepressants in the treatment of adults with chronic medical conditions that may help clinicians to initiate and evaluate the use of antidepressants. The study had 63 randomized controlled trials covering antidepressant...

  • Bupropion modified/extended release: a guide to its use in major depressive disorder.  // Drugs & Therapy Perspectives;Jan2009, Vol. 25 Issue 1, p1 

    The article focuses on the release of the modified bupropion for use in major depressive disorder. Bupropion XR is a second-generation antidepressant with a more convenient new once-daily formulation for the treatment of major depressive disorder. Clinical trials revealed that the drug was...

  • Star-D Sonrası: SaÄŸaltıma Direnen Depresyon (SDD). YAZICI, Olcay // Archives of Neuropsychiatry / Noropsikiatri Arsivi;2009, Vol. 46 Issue 2, p61 

    Although the lack of evidence in literature for the treatment of resistant depression has not been totally overcome by Star-D Study, and the basic questions are still unanswered; we can assume that now we have much more reliable data regarding the topic. The recent data can be seen as such: 1....

  • Use of antidepressants soars.  // Therapy Today;Jul2009, Vol. 20 Issue 6, p4 

    The article reports on the increasing use of antidepressants in England. In 2007, a total of 36 million prescriptions were given out. According to politicians and experts working in the field of depression, it was important that alternative therapies should be made available to counter the...

  • Safety of Hypericum extract in mildly to moderately depressed outpatients; A review based on data from three randomized, placebo- controlled trials.  // Alternative Medicine Review;Dec2004, Vol. 9 Issue 4, p456 

    Discusses research being done on the safety of Hypericum extract in mildly to moderately depressed patients. Reference to a study by R. D. Trautmann-Sponsel and A. Dienel, published in a 2004 issue of the "Journal of Affective Disorders"; Antidepressant drugs regarded by patients, medical...

  • What are SSRI antidepressants?  // Network Magazine of the Canadian Women's Health Network;Spring/Summer2006, Vol. 8 Issue 3/4, p6 

    The article discusses about selective-serotonin reuptake inhibitor (SSRI) in Canada. SSRIs are a group of drugs commonly prescribed for depression and anxiety. These drugs are sold under brand names such as Prozac, Paxil, Zolof, Celexa, Luvox and effexor. Over 15 million prescriptions for SSRI...

  • Tandem regulation of phosphoinositide signaling and acute behavioral effects induced by antidepressant agents in rats. Tyeryar, Kimberly R.; Undie, Ashiwel S. // Psychopharmacology;Aug2007, Vol. 193 Issue 2, p271 

    Antidepressants increase synaptic monoamine concentrations, but the subsequent signaling events that produce the beneficial clinical effects remain unclear. Diverse antidepressants increase CDP-diacylglycerol, a crucial step in phosphoinositide signaling. Serotonin 5HT2 receptors, implicated in...

  • The antidepressant debate. Moncrieff, Joanna // British Journal of Psychiatry;Mar2002, Vol. 180, p193 

    The author reflects on the debate in the medical literature concerning the efficacy of antidepressant drugs. She discloses that several studies and researches had proven already that the intake of antidepressants promote various adverse effect. She particularly regards its impact to depressive...

  • What prevents relapse best. Cohen, Sharon; Doheny, Kathleen; Bloomquist, Michele // Shape;Sep2003, Vol. 23 Issue 1, p90 

    Reports on benefits of taking antidepressants for a year or longer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics